使用高强度他汀类药物策略。是否遵循指导方针?

Y. C. Costa, V. Mauro, Adrián Charask, Enrique B. Fairman, Hugo Buhezo, C. Barrero
{"title":"使用高强度他汀类药物策略。是否遵循指导方针?","authors":"Y. C. Costa, V. Mauro, Adrián Charask, Enrique B. Fairman, Hugo Buhezo, C. Barrero","doi":"10.7775/RAC.86.1.11430","DOIUrl":null,"url":null,"abstract":"Background: Secondary prevention in patients < 76 years with history of a vascular event or previous revascularization includes the use of high intensity-statin therapy. Objective: The aim of this study is to evaluate the 1-year adherence to treatment since patients’ discharge from the coronary care unit. Methods: We conducted a prospective study of consecutive patients between January and November 2015. Median follow-up was 9 months. Results: A total of 210 patients were included; 83% were men and median age was 59 years (52-67.5). Most patients (74.5%) were discharged with atorvastatin 40 mg/day, 19% with rosuvastatin 20 mg/day, 2.7% with atorvastatin 80 mg/day and 3.9% with rosuvastatin 40 mg/day. Half of the patients continued with high-intensity statins, 28% reduced the dose and 22% stopped the treatment. Conclusions: Only half of the patients with high vascular risk or history of recent revascularization continues with the treatment after one year.","PeriodicalId":447734,"journal":{"name":"Argentine Journal of Cardiology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Use of High-Intensity Statin Strategy. Are the Guidelines Followed?\",\"authors\":\"Y. C. Costa, V. Mauro, Adrián Charask, Enrique B. Fairman, Hugo Buhezo, C. Barrero\",\"doi\":\"10.7775/RAC.86.1.11430\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Secondary prevention in patients < 76 years with history of a vascular event or previous revascularization includes the use of high intensity-statin therapy. Objective: The aim of this study is to evaluate the 1-year adherence to treatment since patients’ discharge from the coronary care unit. Methods: We conducted a prospective study of consecutive patients between January and November 2015. Median follow-up was 9 months. Results: A total of 210 patients were included; 83% were men and median age was 59 years (52-67.5). Most patients (74.5%) were discharged with atorvastatin 40 mg/day, 19% with rosuvastatin 20 mg/day, 2.7% with atorvastatin 80 mg/day and 3.9% with rosuvastatin 40 mg/day. Half of the patients continued with high-intensity statins, 28% reduced the dose and 22% stopped the treatment. Conclusions: Only half of the patients with high vascular risk or history of recent revascularization continues with the treatment after one year.\",\"PeriodicalId\":447734,\"journal\":{\"name\":\"Argentine Journal of Cardiology\",\"volume\":\"34 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Argentine Journal of Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7775/RAC.86.1.11430\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Argentine Journal of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7775/RAC.86.1.11430","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:76岁以下有血管事件史或既往血运重建术患者的二级预防包括使用高强度他汀类药物治疗。目的:本研究的目的是评估冠心病患者出院后1年的治疗依从性。方法:我们于2015年1月至11月对连续患者进行前瞻性研究。中位随访为9个月。结果:共纳入210例患者;83%为男性,中位年龄为59岁(52-67.5岁)。大多数患者(74.5%)出院时使用阿托伐他汀40 mg/天,19%使用瑞舒伐他汀20 mg/天,2.7%使用阿托伐他汀80 mg/天,3.9%使用瑞舒伐他汀40 mg/天。一半的患者继续使用高强度他汀类药物,28%的患者减少剂量,22%的患者停止治疗。结论:只有一半的高危或近期有血运重建史的患者在一年后继续治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Use of High-Intensity Statin Strategy. Are the Guidelines Followed?
Background: Secondary prevention in patients < 76 years with history of a vascular event or previous revascularization includes the use of high intensity-statin therapy. Objective: The aim of this study is to evaluate the 1-year adherence to treatment since patients’ discharge from the coronary care unit. Methods: We conducted a prospective study of consecutive patients between January and November 2015. Median follow-up was 9 months. Results: A total of 210 patients were included; 83% were men and median age was 59 years (52-67.5). Most patients (74.5%) were discharged with atorvastatin 40 mg/day, 19% with rosuvastatin 20 mg/day, 2.7% with atorvastatin 80 mg/day and 3.9% with rosuvastatin 40 mg/day. Half of the patients continued with high-intensity statins, 28% reduced the dose and 22% stopped the treatment. Conclusions: Only half of the patients with high vascular risk or history of recent revascularization continues with the treatment after one year.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信